Repligen earnings for the third quarter of 2026 showed revenue rising 11% to $209.3 million, while an intangible asset impairment contributed to an operating loss. The bioprocessing technology company reported a GAAP loss of $0.68 per share, compared with earnings of $0.26 per share a year earlier.

Key Takeaways

  • Quarterly revenue exceeded the cited analyst estimate of $206.62 million.
  • Adjusted earnings rose to $0.53 per share from $0.46 a year earlier.
  • Repligen completed its acquisition of BioLife Solutions.

Repligen earnings show revenue growth alongside GAAP loss

Repligen reported its results on October 27, 2026. Third-quarter revenue rose from $188.8 million in the same period of 2025, while organic revenue grew 12.5%.

The company reported a $29.5 million GAAP operating loss, driven by an intangible asset impairment charge. Adjusted operating income was positive at $33.3 million, illustrating the difference between the reported and adjusted measures.

Gross margin was 53.0%, compared with 53.2% a year earlier.

BioLife acquisition expands cell therapy presence

Repligen completed the acquisition of BioLife Solutions, a deal expected to strengthen its presence in cell therapy. The available results summary did not specify the transaction price.

The Waltham, Massachusetts-based company supplies technologies used to manufacture biologic drugs. Its offerings include filtration and fluid management, chromatography, proteins and process analytics.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.